
    
      Project title: Platelet rich fibrin (PRF) membranes in lateral alveolar ridge augmentation.

      Background Tooth loss induce extensive resorption of the alveolar ridge, thereby compromising
      implant placement in a correct anatomical position. Therefore, various procedures for
      alveolar ridge augmentation have been introduced. The most frequently used procedure includes
      lateral alveolar ridge augmentation by an autogenous bone graft harvested from an intraoral
      donor site. The bone graft is often covered by a resorbable collagen barrier membrane and an
      anorganic bovine bone substitute to minimize the resorption of the autogenous bone graft
      during the healing period. However, it has been indicated that the use of a barrier membrane
      increases the risk of bone graft exposure, thereby significantly compromising the treatment
      outcome.

      Biological platelet rich fibrin (PRF) membranes derived from a blood sample of the patient
      has been introduced to accelerate soft tissue as well as bone healing. In vitro studies have
      revealed that PRF membranes may enhance proliferation and differentiation of osteoblasts,
      collagen protein production, and angiogenesis. The potential benefit of PRF membranes for
      lateral alveolar ridge augmentation has been evaluated in one animal experiment only.
      However, the use of PRF membranes in lateral alveolar ridge augmentation has not been
      addressed in humans. Clinical studies using PRF membranes have indicated accelerated soft
      tissue and bone healing in periodontal therapy, soft tissue reconstructive surgery, and
      vertical alveolar ridge augmentation using the maxillary sinus lift procedures.

      Purpose of investigations, including hypothesis

      The purpose of the investigations is to evaluate the treatment outcome after lateral alveolar
      ridge augmentation by using an autogenous bone graft covered by 1) a PRF membrane (test
      group) or 2) an anorganic bovine bone substitute and a resorbable collagen barrier membrane
      (control group) in a randomized, controlled clinical trial (RCT) with focus on:

      Study 1: Outcome of the oral implant treatment with focus on clinical, radiographic,
      esthetic, and socioeconomical parameters.

      Study 2: Soft tissue and bone healing with focus on volumetric changes. Study 3: Bone healing
      by using histological and stereological methods. It is the investigator's hypothesis that
      there are no differences between the test and control groups.

      Material and methods A total of 40 patients with a healthy dentition are included at random
      within the test (n=20) and control (n=20) group in the study.

      Lateral alveolar ridge augmentation The lateral alveolar ridge augmentation is performed as
      previously described. An autogenous bone graft is initially harvested from the mandible via
      an intraoral approach. The lateral aspect of the posterior part of the mandible is exposed by
      using a standard incision technique and the harvested bone graft is adjusted and fixated with
      two titanium mini-screws as a lateral block graft. In the test group, a venous blood sample
      (80 ml) via puncture of a vein in the fossa cubiti is collected and centrifuged according to
      a previously described method. A total of 20 ml of the 80 ml collected blood is collected for
      later biochemical characterization of the blood sample and the PRF membrane. The obtained PRF
      membrane is adjusted and placed to cover the bone graft. In the control group, the lateral
      block graft is covered with anorganic bovine bone substitute (Bio-Oss, Geistlich Pharma,
      Switzerland) and a collagen membrane (Bio-Gide, Geistlich Pharma, Switzerland). Preoperative
      prophylactic antibiotic treatment (Amoxicillin/Clavulanic acid, 1000/250 mg) is given as well
      as postoperative pain control (Ibuprofen, 400 mg x 4 daily).

      Implant installation After a healing period of 6 month, a standard incision technique is used
      to expose the augmented alveolar ridge. The previously inserted mini-screws are removed and
      an implant (Bone Level, Straumann, Switzerland) with a cover screw is installed according to
      the manufacture's recommendation. Before implant installation, a cylindrical biopsy of the
      augmented bone and the resident alveolar bone is retrieved perpendicularly to the lateral
      aspect of the augmented ridge by a 2-mm trephine bur for later histological and stereological
      evaluation. The biopsy cavity is filled with locally harvested autogenous bone chips
      (Safescraper, Divisione Medical Meta, Italy). If the buccal bone thickness after implant
      installation is less than 2 mm, localized alveolar ridge augmentation is performed by using
      also locally harvested autogenous bone chips covered by an anorganic bovine bone substitute
      and a resorbable collagen membrane. Preoperative prophylactic antibiotic treatment
      (Amoxicillin/Clavulanic acid, 1000/250 mg) is given as well as postoperative pain control
      (Ibuprofen, 400 mg x 4 daily).

      Prosthetic treatment After a healing period of 6 month, a healing abutment is placed (Nobel
      Biocare, Switzerland). After an additional 2-week soft tissue healing period, the healing
      abutment is removed and an individual definitive zirconium abutment and an all-ceramic crown
      with a framework of alumina oxide and veneering porcelain is placed.

      Data analysis, including calculation of sample size Data management and analysis including
      calculation of descriptive statistics are performed in collaboration with a biostatistician.
      The statistical analyses will mainly include t-test, Pearson's correlation analysis, and
      analysis of variance. Power calculations are based on differences in patient satisfaction and
      changes in marginal bone level in a previous study involving replacement of a single tooth
      with 2 different protocols of implant treatment. When the calculation of the group size is
      based on the figures for patient satisfaction measured on a VAS scale (with a maximum of 100)
      after treatment (a difference between treatments of 6.81 and a standard deviation of 6.82),
      17 patients should be included in each group to detect a difference at the 5%-level with a
      power of 80%. When the power calculation is based on the observed changes in marginal bone
      level from insertion of the implant to abutment connection (a change of 0.65 mm and a
      standard deviation of 0.65), 17 patients in each group reaches a power of 97% at the
      5%-level. With 15% to cover any drop-outs, each treatment group should include 20 patients.

      Bone biopsy storage The previously describes bone biopsies are kept during the histological
      processing at Aarhus University. All material will be anonymous and destroyed at the end of
      the project.

      Ethical aspects, including risks, data management, and publication The two described lateral
      alveolar ridge augmentation procedures are both commonly used in the clinic. As previously
      described, potential benefits and disadvantages are presently unknown, because no comparative
      study has been performed. The described implant treatment is performed according standard
      procedure. It has been documented that lateral alveolar ridge augmentation and implant
      treatment are characterized by minimal risk of complication, including pain, swelling, and
      inflammation. The bone harvesting procedure includes a minimum risk for compromised
      sensibility of the lip and tongue. The change in sensibility is in most cases temporarily,
      but can rarely be permanent. The study involves a total of 3 segmented CBCT scanning
      procedures and 5 intra-oral radiographic images corresponding to a total radiation dose
      equivalent to 60 days of background radiation. Therefore, the total radiation dose of the
      patients seems from an ethical point of view acceptable. In conclusion, the described study
      is characterized by a very low risk of complications. If failure of the augmentation
      procedure or implant treatment occurs, prosthetic treatment involving a conventional, fixed
      bridge can always be performed. If unexpected adverse events occur, the project will be
      cancelled.

      The all surgical procedures will be performed by the applicant, who is an oral and
      maxillofacial surgeon with extensive clinical skills within the field of bone augmentation
      and implant treatment. Moreover, the prosthetic part of the treatment will be performed by
      two dentists with extensive clinical skills within the field of implant prosthetics. The
      patients will be covered by the same health assurance as all patients at the Department of
      Dentistry, Aarhus University.

      PRF membranes derived from the patient's own blood using a chair-side method have recently
      been commercially available. These membranes may enhance soft tissue as well as bone healing,
      but the hypothesis has not been validated in a randomized controlled clinical trial. The
      described studies will provide new and important knowledge, which from a clinical,
      economical, and scientific perspective is important.

      The studies are performed according to the Declaration of Helsinki and internationally
      accepted guidelines for randomized controlled clinical trials (RCT), and has been approved in
      accordance with Danish regulations by the Committee of Ethics, the Central Denmark Region
      (Project-ID: 44710) 2014 before the start of the study. The physical and mental integrity of
      the patients will be respect. The project is performed as Ph.D. collaboration project between
      Aarhus University and Aarhus University Hospital after approval by the Danish Data Protection
      Agency. All processing of personal data and free movement of such data will be in according
      to Danish law. The results will be published in international scientific journals.

      Funding The project has been developed by the applicant in collaboration with the supervisors
      without commercial influences. Aarhus University has supported the project and used material
      including implants will be provided for free by the manufactures (Nobel Biocare and Geistlich
      Pharma, Switzerland). These companies will not have any influence on the project, including
      publication of the results.

      The patients are recruited among patients referred to the Department of Dentistry, Aarhus
      University from dentist for bone augmentation and implant treatment. If insufficient numbers
      of patients are referred, advertisement of the project will be announced by e-mail or within
      the Danish Dental Journal (Tandl√¶gebladet). Detailed written and oral information about the
      project including all potential risks will be given by the applicant in a separate,
      undisturbed clinic at the Section for Oral and Maxillofacial Surgery and Oral Pathology,
      Department of Dentistry, Aarhus University. The patients will be provided with the written
      information at the time of the initial examination. All patients will have sufficient time to
      read the information before the oral information is given. Moreover, the patients will be
      given sufficient time (1 week) to consider their participation in the study before the
      informed consent form is signed and dated by the patient as well as the applicant. The
      patients will receive the original version, while the applicant will keep a copy as part of
      the study documentation. The patients are provided with the opportunity to have an assessor
      during the entire information and approval phase.

      The patients will be treated at the Department of Dentistry, Health, Aarhus University and
      the Department of Oral and Maxillofacial Surgery, Aarhus University Hospital, Denmark.
    
  